InMode stock steady amid US sales drop, buoyed by international growth and recurring revenue.

InMode's stock remains rangebound due to declining US platform sales, but international expansion and recurring consumables revenue help stabilize the company. Despite a downgrade from 'strong buy' to 'buy' due to industry softness, macroeconomic challenges, and management frustrations, InMode's strong cash position and proprietary technology provide a competitive edge. Key growth drivers include international markets, new product launches, and a recovering economy, though near-term gains are limited by rising costs and uncertain US demand.

InMode's stock is trading at USD 14.26 on Pluang as of Sep 26, 2026 10:41 WIB, showing a modest 0.49% gain for the day. This price sits closer to its 52-week low of USD 12.76 than its high of USD 16.62, indicating limited upside in the current range. The market cap stands at $816.55 million, reflecting its mid-sized position in the health sector. The typical hold time of 29 days on Pluang suggests moderate investor engagement with this stock.